Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2016 075 417.7 |
96 | EP file number | EAKZ | 16 70 2812.5 |
86 | WO file number | WAKZ | PCT/IB2016/050415 |
97 | EP publication number | EPN | 3250592 |
87 | WO publication number | WPN | 2016120810 |
54 | Designation/title | TI | ANTI-TRANSTHYRETIN-ANTIKÖRPER |
51 | IPC main class | ICM (ICMV) | C07K 16/18 (2006.01) |
22 | DE application date | DAT | Jan 28, 2016 |
96 | EP application date | EAT | Jan 28, 2016 |
86 | WO application date | WAT | Jan 28, 2016 |
43 | Date of first publication | OT | Aug 4, 2016 |
| Date of publication of grant | PET | Oct 5, 2022 |
71/73 | Applicant/owner | INH | Novo Nordisk A/S, Bagsvard, DK; University Health Network, Toronto, Ontario, CA |
72 | Inventor | IN | LIU, Yue, Foster City, California 94404, US; NIJJAR, Tarlochan S., Orinda, California 94563, US; CHAKRABARTTY, Avijit, Vaughn, Ontario L4K 2E1, CA; HIGAKI, Jeffrey, N., San Mateo, CA 94402, US |
74 | Representative | VTR | Stolmár & Partner Patentanwälte PartG mbB, 80331 München, DE |
| Address for service | | Stolmár & Partner Patentanwälte, 80331 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201562109002 P Jan 28, 2015
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201562266556 P Dec 11, 2015
|
| Due date | FT FG | Jan 31, 2026 Annual fee for the 11th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003250592A1 Searchable text:
EP000003250592A1 Original document:
EP000003250592B1 Searchable text:
EP000003250592B1 Original document:
WO002016120810 Searchable text:
WO002016120810 |
43 | Date of first publication | EVT | Aug 4, 2016 |
| Date of the first transfer into DPMAregister | EREGT | Dec 6, 2017 |
| Date of the (most recent) update in DPMAregister | REGT | Jan 11, 2025 (Show all update days)(Hide all update days)- Jan 11, 2025
- Jun 27, 2024; Jan 6, 2024; Sep 28, 2023; Aug 24, 2023; Apr 27, 2023; Mar 18, 2023; Mar 1, 2023; Jan 4, 2023; Oct 27, 2022; Sep 20, 2022; Sep 15, 2022
- Historical data not available for this/these date(s)
- Dec 6, 2017
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 6)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Mar 17, 2023 |
| Issue number | HN | 17 |
| Year | PJ | 2023 |
| Publication date | VT | Apr 27, 2023 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Novo Nordisk A/S, Bagsvard, DK; University Health Network, Toronto, Ontario, CA |
71/73 | Previous applicant/owner | INHF | Prothena Biosciences Limited, Dublin, IE, University Health Network, Toronto, Ontario, CA |
| Date of update of the procedure | REGT | Apr 27, 2023 |